Torii Pharmaceutical Co., Ltd.

TSE:4551 Stock Report

Market Cap: JP¥141.2b

Torii Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

Torii Pharmaceutical's earnings have been declining at an average annual rate of -31.2%, while the Pharmaceuticals industry saw earnings growing at 6.7% annually. Revenues have been growing at an average rate of 6.4% per year. Torii Pharmaceutical's return on equity is 4.4%, and it has net margins of 9%.

Key information

-31.2%

Earnings growth rate

-31.2%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate6.4%
Return on equity4.4%
Net Margin9.0%
Next Earnings Update12 Feb 2025

Recent past performance updates

Recent updates

Torii Pharmaceutical Co., Ltd.'s (TSE:4551) Business Is Yet to Catch Up With Its Share Price

Jan 22
Torii Pharmaceutical Co., Ltd.'s (TSE:4551) Business Is Yet to Catch Up With Its Share Price

Revenue & Expenses Breakdown

How Torii Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4551 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2458,8395,27614,5452,875
30 Jun 2457,2485,25414,1122,440
31 Mar 2456,2785,28514,1591,965
31 Dec 2354,6384,11914,0143,490
30 Sep 2352,7133,45616,1913,383
30 Jun 2351,4933,18516,1623,491
31 Mar 2349,7472,77416,0283,542
31 Dec 2248,8963,94415,9441,661
30 Sep 2248,8653,99216,7751,410
30 Jun 2248,5343,97517,4351,084
31 Mar 2248,0483,82018,104900
31 Dec 2146,9873,37418,591832
30 Sep 2144,9653,22518,134650
30 Jun 2143,3982,93917,747646
31 Mar 2142,0283,06916,659647
31 Dec 2041,7003,49516,165596
30 Sep 2041,8503,40919,252-2,131
30 Jun 2042,1712,97319,450-1,553
31 Mar 2043,408-29320,185-929
31 Dec 1942,99827,36720,8640
30 Sep 1948,32825,38218,6403,625
30 Jun 1952,68425,81019,4913,918
31 Mar 1957,78229,11720,5684,108
31 Dec 1862,5511,16425,7550
30 Sep 1863,9524,19521,4284,193
30 Jun 1864,5964,50521,3534,440
31 Mar 1864,4574,89921,5944,472
31 Dec 1764,1354,71821,5244,608
30 Sep 1762,1643,85521,2124,593
30 Jun 1761,2833,11721,1454,838
31 Mar 1760,0742,42421,1084,764
31 Dec 1660,2062,83921,0254,654
30 Sep 1661,3052,95121,2005,147
30 Jun 1661,9573,37821,1554,925
31 Mar 1662,8203,79821,0175,160
31 Dec 1562,3783,52721,0155,237
31 Dec 1458,0893,39320,2144,878
30 Sep 1457,1073,03119,8895,664
30 Jun 1456,5172,97219,8856,148
31 Mar 1458,1093,35219,8716,662

Quality Earnings: 4551 has high quality earnings.

Growing Profit Margin: 4551's current net profit margins (9%) are higher than last year (6.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4551's earnings have declined by 31.2% per year over the past 5 years.

Accelerating Growth: 4551's earnings growth over the past year (52.7%) exceeds its 5-year average (-31.2% per year).

Earnings vs Industry: 4551 earnings growth over the past year (52.7%) exceeded the Pharmaceuticals industry 9.4%.


Return on Equity

High ROE: 4551's Return on Equity (4.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 17:48
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Torii Pharmaceutical Co., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hidemaru YamaguchiCitigroup Inc
Kazuaki HashiguchiDaiwa Securities Co. Ltd.
Takashi AkahaneTokai Tokyo Intelligence Laboratory Co., Ltd.